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Abstract
Uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists with
fast off-rate (UFO) may represent promising drug candidates for various
neurodegenerative disorders. In this study, we report that bis(propyl)cognitin, a novel dimeric acetylcholinesterase inhibitor and γ-aminobutyric
acid subtype A receptor antagonist, is such an antagonist of NMDA receptors.
In cultured rat hippocampal neurons, we demonstrated that bis(propyl)cognitin voltage-dependently, selectively, and moderately inhibited NMDAactivated currents. The inhibitory effects of bis(propyl)-cognitin increased with
the rise in NMDA and glycine concentrations. Kinetics analysis showed that
the inhibition was of fast onset and offset with an off-rate time constant of
1.9 s. Molecular docking simulations showed moderate hydrophobic
interaction between bis(propyl)-cognitin and the MK-801 binding region in the
ion channel pore of the NMDA receptor. Bis(propyl)-cognitin was further found
to compete with [3H]MK-801 with a Ki value of 0.27 μm, and the mutation of
NR1(N616R) significantly reduced its inhibitory potency. Under glutamatemediated pathological conditions, bis(propyl)-cognitin, in contrast to
bis(heptyl)-cognitin, prevented excitotoxicity with increasing effectiveness
against escalating levels of glutamate and much more effectively protected
against middle cerebral artery occlusion-induced brain damage than did
memantine. More interestingly, under NMDA receptor-mediated physiological
conditions, bis(propyl)-cognitin enhanced long-term potentiation in
hippocampal slices, whereas MK-801 reduced and memantine did not alter
this process. These results suggest that bis(propyl)-cognitin is a UFO
antagonist of NMDA receptors with moderate affinity, which may provide a
pathologically activated therapy for various neurodegenerative disorders
associated with NMDA receptor dysregulation.
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Introduction
Neurodegenerative disorders are among the leading cause of
death in the elderly, and this medical problem is expected to become
more serious as the population continues to age. N-Methyl-D-aspartate
(NMDA)3 receptor overactivation-induced excitotoxicity is clearly
implicated in a variety of acute and chronic neurodegenerative
disorders (1,–4). Thus, the NMDA receptor has been considered an
attractive therapeutic target for the development of neuroprotectants.
However, the NMDA receptor, as the major excitatory
neurotransmitter receptor in the central nervous system, mediates
many important physiological processes, such as excitatory
neurotransmission, synaptic plasticity, learning and memory, and cell
survival (5,–8). The therapeutic potential of many NMDA receptor
antagonists, therefore, was limited, and they failed in clinical trials
because of their psychotropic side effects and memory-impairing
effects resulting from the blockade of NMDA receptor-mediated
physiological activities (9, 10). Clinically well tolerated and effective
NMDA receptor antagonists for the therapy of neurodegenerative
disorders have been pursued over the past several decades.
The strategies applied to develop effective and well tolerated
neuroprotective drugs are based on the principle that drugs should
interact with their targets only during states of pathological and not
physiological activation. Such drugs have been coined pathologically
activated therapeutic (PAT) drugs by Lipton (11). For the treatment of
neurodegenerative disorders accompanied by NMDA receptor-mediated
excitotoxicity, uncompetitive NMDA receptor antagonists with fast offrate (UFO), but not competitive and noncompetitive ones, fit in with
the PAT strategy. An uncompetitive antagonist is defined as a drug
whose inhibitory effect is contingent upon prior activation of the
channel by agonist, and a fixed concentration of antagonist blocks the
response to high concentrations of agonist to a greater extent than the
response to low concentrations of agonist (11). A clear advantage of
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compounds of this type is that they preferentially blocked
overactivated (in a tonic rather than phasic manner) channels while
sparing physiological neurotransmission mediated by NMDA receptors
(12,–14). However, for uncompetitive antagonists, the off-rate and
affinity further determine the clinical tolerability. Taking dizocilpine
(MK-801) as an example, because it binds very tightly with and
dissociates very slowly from the receptor, it blocks excessive as well as
normal activation, resulting in deleterious side effects. Thus,
uncompetitive NMDA receptor antagonists with moderate to low
receptor affinity and with fast on/off-rate kinetics have been the center
of interest in the search for neuroprotective drugs with beneficial
therapeutic potentials for the treatment of various acute and chronic
neurodegenerative disorders (10, 15,–17).
Over the past decade, our group has developed a series of
dimeric acetylcholinesterase (AChE) inhibitors derived from tacrine
linked with different numbers of methylene (-CH2-) groups (18). These
dimers have been demonstrated to inhibit AChE and γ-aminobutyric
acid subtype A (GABAA) receptors in a tether-dependent manner (19,
20). The reduction of acetylcholine breakdown by AChE inhibitors may
increase acetylcholine levels in the brain and contribute to learning
and memory. Furthermore, blockade of GABAA receptors can increase
the release of acetylcholine (21) and facilitates long term potentiation
(LTP) induction (22), whereas activation of GABAA receptors may
deteriorate aging-associated memory decline (23). In our previous
study, bis(heptyl)-cognitin (also known as bis(7)-tacrine), heptylenelinked tacrine dimer, has been found to prevent glutamate-induced
excitotoxicity by blocking NMDA receptors. However, the effectiveness
of bis(heptyl)-cognitin neuroprotection decreases with the increase of
glutamate concentration (24). Therefore, besides their AChE and
GABAA receptor inhibitions in a tether-dependent manner, at the
beginning of this study, we speculated that this series of
multifunctional dimers might possess tether-dependent effects on
NMDA receptors and different manners of neuroprotection. By
comparison of their actions on NMDA receptors, bis(propyl)-cognitin
emerges as a promising neuroprotective drug candidate among these
novel dimers. We demonstrate that this dimer is an uncompetitive
NMDA receptor antagonist with moderate affinity, fast off-rate,
effective neuroprotective activities against glutamate-induced neuronal
cell death without obvious cytotoxicity in vitro and middle cerebral
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artery occlusion (MCAO)-induced brain damage in vivo, and
enhancement of LTP. These findings strongly suggest that this dimer
may be developed to a PAT drug possessing considerable therapeutic
potential for various associated neurodegenerative disorders.

Experimental Procedures
Primary Neuron Cultures
Primary cultured hippocampal neurons were obtained from 18day-old Sprague-Dawley rat embryos as previously described with
modifications (25). Briefly, The hippocampi were dissected and
incubated with 0.25% trypsin at 37°C for 12 min. Cells were then
mechanically dissociated by using a Pasteur pipette with a firenarrowed tip in culture medium and plated at a density of 2 × 105
cells/ml on 35-mm culture dishes precoated with poly-l-lysine (10
μg/ml). Cells were maintained in neurobasal/B27 medium containing
0.5 m glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin
under a humidified atmosphere of 5% CO2, 95% air at 37°C. Halfchanges of medium were done twice weekly. Cells were used for
electrophysiological recording 7–15 days after plating.
Cerebellar granule neurons (CGNs) were prepared from 8-dayold Sprague-Dawley rats (the animal care facility, Hong Kong
University of Science and Technology) as described previously (24).
Briefly, neurons were seeded on 96-well plates precoated with poly-llysine (10 μg/ml) at a density of 2 × 106 cells/ml in basal modified
Eagle's medium containing 10% fetal bovine serum, 25 m KCl, 2 m
glutamine, and penicillin (100 units/ml)/streptomycin (100 μg/ml).
Cytosine arabinoside (10 μm) was added to the culture medium 24 h
after plating to limit the growth of non-neuronal cells. With the use of
this protocol, 95–99% of the cultured cells were granule neurons. All
experiments were performed in CGNs at 7 or 8 days in vitro.

HEK293T Cell Culture and Transfection
HEK293T cells (ATCC, Manassas, VA) were grown as a
monolayer using passage numbers less than 25 and maintained in
Dulbecco's modified Eagle's medium (Invitrogen), supplemented with
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10% fetal bovine serum (Invitrogen) and 2 m L-glutamine in a
humidified incubator at 37°C with 5% CO2. At 1 day prior to
transfection, exponentially growing cells were plated at a density of 1
× 105 cells/ml on 35-mm culture dishes precoated with poly-L-lysine
(10 μg/ml). The cells were transiently transfected using
Lipofectamine/PLUS reagents (Invitrogen) with a ratio of cDNA for rat
NMDA receptor subunits for NR1-1a/NR2A (gift of Dr. Anne
Stephenson from the Department of Pharmaceutical and Biological
Chemistry, School of Pharmacy, University of London) of 1:3. An NR11a (N616R) mutation was introduced by site-directed mutagenesis
using the QuikChange kit (Stratagene, La Jolla, CA) according to the
manufacturer's directions and confirmed by DNA sequencing. Following
transfection, the cells were maintained for 24 h in a glutamine-free
medium containing 100 μm D(-)-2-amino-5-phosphonopentanoic acid
and 200 μm ketamine to prevent NMDA receptor-mediated
excitotoxicity.

Whole-cell Electrophysiological Recordings
Whole-cell patch clamp recordings were carried out at room
temperature (22–24°C) on the stage of an inverted phase-contrast
microscope using an Axopatch 200B patch amplifier (Axon
Instruments, Burlingame, CA). Before each experiment, the culture
medium was removed, and the cells were rinsed completely and
continuously superfused with a solution containing 150 m NaCl, 5
m KCl, 0.25 m CaCl2, 10 m glucose, 0.001 m glycine, 0.001 m
tetrodotoxin, 0.01 m (−)-bicuculline methiodide, and 10 m HEPES
(the pH was adjusted to 7.4 with NaOH, and the osmolarity was
adjusted to ∼340 mos with sucrose). The low concentration of Ca2+
was used to minimize the calcium-dependent desensitization of NMDAactivated currents. Pipettes pulled from borosilicate glass (TW-150F,
World Precision Instruments, Sarasota, FL) had resistances of 2–4
megaohms when filled with pipette solution containing 140 m CsCl,
10 m EGTA, 10 m HEPES, and 5 m MgATP with pH 7.3 and 315
mos in osmolarity. A small patch of membrane underneath the tip of
the pipette was aspirated to form a gigaseal, and then a more negative
pressure was applied to rupture it, thus establishing a whole-cell
configuration. The adjustment of capacitance compensation and series
resistance compensation was done before recording the membrane
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currents. The holding potential was set at −50 mV except when
otherwise indicated. Data were acquired using pClamp 9.0 software
(Axon Instruments). Currents were filtered at 2 kHz and digitized at 5
kHz.

Drug Application
Drugs used in the experiments included NMDA, AMPA, kainate,
tacrine, memantine, MK-801, tetrodotoxin, and (−)-bicuculline
methiodide. All of these drugs were purchased from Sigma. Bis(n)cognitins were prepared according to the method described previously
(19). Each drug was dissolved daily in the Mg2+-free external solution
just before use and applied with a fast step perfusion system (SF-77B;
Warner Instruments, Hamden, CT) through 3-barrel square glass
tubing. The distance from the tube mouth to the cell examined was
about 100 μm. The application of each drug could be driven by gravity
and controlled by the corresponding valve. The solution exchange rate
was estimated according to Chen et al. (26) with a time constant of
2.38 ± 0.82 ms (n = 21, mean ± S.E.). Cells or patches were
constantly bathed in the normal external solution flowing from one
tube connected to a larger reservoir between drug applications (0.5–
0.8 ml/min).

Molecular Docking Analysis
The homology model of the ion channel of NMDA receptors was
constructed based on the x-ray crystal structure of the potassium
channel KcsA (Protein Data Bank code 1BL8), and performed using
ICM sequence-structure alignment and the BuildModel algorithm. ICM
sequence-structure alignment is based on the primary sequences of
subunits of NR1, NR2B, and the primary sequence of potassium
channel KcsA (Escherichia coli). The homology model was optimized by
Monte Carlo minimization. Three independent runs of the refinement
procedure were performed, each run including 100,000 Monte Carlo
minimization steps. The ICM Protein Health tool was used to check the
quality of the refinement. Molecular docking was performed using the
ICM-Pro 3.4-8a program (Molsoft). According to the ICM method, the
molecular system was described using internal coordinates as
variables. Energy calculations were based on the ECEPP/3 force field
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with a distance-dependent dielectric constant. The biased probability
Monte Carlo minimization procedure was used for global energy
optimization. The binding between the compounds and the NMDA
receptor was evaluated with a full-atom ICM ligand binding score
calculated as follows, Sbind = Eint + TΔSTor + Evw + 1Eel + 2Ehb + 3Ehp
+ 4Esf, where Evw, Eel, Ehb, Ehp, and Esf are van der Waals,
electrostatic, hydrogen bonding, and nonpolar and polar atom
solvation energy differences between bound and unbound states,
respectively. Eint is the ligand internal strain, ΔSTor is its conformational
entropy loss upon binding, T = 300 K, and αi are ligand- and receptorindependent constants. A more negative binding score represents a
more favorable binding interaction.

Receptor-ligand Binding Assay
The binding assay was performed as described (24) with
modifications. Synaptic plasma membrane was prepared from the
cerebella of 15-day-old Sprague-Dawley rats by using discontinuous
sucrose density gradients. The receptor ligand binding was performed
in triplicate using 150–200 μg of synaptic plasma membrane protein
and 4 n [3H]MK-801 (American Radiolabeled Chemicals Inc., St.
Louis, MO) incubated with different concentrations of testing
compounds; nonspecific binding was determined by an excess of the
unlabeled MK-801. After collecting the samples on Whatman GF/B
filters by rapid filtration with an MD-24 sample harvester, filtrated
tissue on filters was soaked into scintillation mixtures overnight and
measured in a scintillation counter (Wallac 1209, Rackbeta (Turku,
Finland)). Specific 3H-ligand binding to receptors was determined by
subtracting the nonspecific count from the total, which is defined by
0.1 m unlabeled MK-801.

Measurement of Neurotoxicity
The percentage of surviving neurons in the presence of
bis(propyl)-cognitin and/or glutamate was estimated by determining
the activity of mitochondrial dehydrogenases with a 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(24). The assay was performed according to the specifications of the
manufacturer (MTT kit I, Roche Applied Science). Briefly, the neurons
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were cultured in 96-well plates, 10 μl of 5 mg/ml MTT labeling reagent
was added to each well containing cells in 100 μl of medium, and the
plate was incubated for 4 h in a humidified incubator at 37°C. After the
incubation, 100 μl of the solvating solution (0.01  HCl in 10% SDS
solution) was added to each well for 17–18 h. The absorbance of the
samples was measured at a wavelength of 570 nm with 630 nm as a
reference wavelength. Unless otherwise indicated, the extent of MTT
conversion in cells exposed to glutamate is expressed as a percentage
of the control.

Transient Focal Cerebral Ischemia
The MCAO model was made on Male Sprague-Dawley rats (280–320 g)
after anesthesia by injection of chloral hydrate (350 mg/kg
intraperitoneally) as described previously with minor modifications
(27). Briefly, a nylon filament with a rounded tip was advanced from
the external carotid artery into the lumen of the internal carotid artery
until laser Doppler flowmetry (PF5000, Perimed (Stockholm, Sweden))
showed a sharp decrease of the regional blood flow of middle cerebral
artery to ∼20% of the base-line value. Two hours after onset of
ischemia, reperfusion was allowed by withdrawal of the suture thread.
The animals from the sham group received the same operation
procedure except without the insertion of the nylon filament. 24 h
after the reperfusion, neurological deficits were evaluated by a 3-point
grading scale (28). Immediately after scoring of neurological deficits,
rats were killed with an overdose of 10% chloral hydrate. Brains were
sectioned into seven 2-mm coronal slices by use of a rat brain matrix
(RBM 4000C; ASI Inc., Warren, MI) and stained with 2% 2,3,5triphenyltetrazolium chloride. The infarct volume % = (contralateral
volume − ipsilateral non-ischemic volume)/contralateral volume ×
100%, and the edema extent = (ipsilateral volume − contralateral
volume)/contralateral volume × 100%.

Preparation of Slices
All experiments were carried out on transverse slices of the
Wistar rat hippocampus (males, age 3–4 weeks, weight 40–80 g). The
brains were rapidly removed after decapitation and placed in cold
oxygenated (95% O2, 5% CO2) media. Slices were cut at a thickness
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of 350 μm using a Campden Vibroslice and placed in a storage
container containing oxygenated media at room temperature (20–
22°C) for 1 h. The slices were then transferred to a recording chamber
for submerged slices and continuously superfused at a rate of 5–6
ml/min at 30–32°C. The control media contained 120 m NaCl, 2.5
m KCl, 1.25 m NaH2PO4, 26 m NaHCO3, 2.0 m MgSO4, 2.0 m
CaCl2, 10 m D-glucose. All solutions contained 100 μm picrotoxin
(Sigma) to block GABAA receptor-mediated response.

LTP Recording
The slices were transferred to the recording chamber, in which it was
held submerged between two nylon nets and maintained at 30–32°C.
The chamber consisted of a circular well of a low volume (1–2 ml) and
was perfused constantly at a rate of 4–5 ml/min. Standard
electrophysiological techniques were used to record field potentials. All
experiments were carried out in the dentate gyrus, with presynaptic
stimulation applied to the medial perforant pathway of the dentate
gyrus using a bipolar insulated tungsten wire electrode, and field
excitatory postsynaptic potentials (EPSPs) recorded at a control test
frequency of 0.033 Hz from the middle one-third of the molecular layer
of the dentate gyrus with a glass microelectrode. In each experiment,
an input-output curve (afferent stimulus intensity versus EPSP
amplitude) was plotted at the test frequency. For all experiments, the
amplitude of the test EPSP was adjusted to one-third of maximum (1–
1.2 mV), and base-line synaptic transmission was monitored for 30
min before drug administration or delivering either high or low
frequency stimulation. LTP was evoked by high frequency stimulation
(HFS) consisting of eight trains, each of eight stimuli at 200 Hz,
intertrain interval of 2 s, with the stimulation voltage increased during
the HFS so as to elicit an initial EPSP of the train of double the normal
test EPSP amplitude. Agents tested in this study were perfused over
the slices for 60 min prior to HFS. Control (vehicle alone) and
experimental levels of LTP were measured on slices prepared from the
same hippocampus. Electrical signals were collected with an Axoclamp700B and were analyzed using pClamp 10.2 (Axon Instruments). All
values were normalized to this base line, and all values of LTP reported
here were calculated as the changes in field EPSP amplitude measured
60 min after tetanic stimulation.
[Citation: Journal/Monograph Title, Vol. XX, No. X (yyyy): pg. XX-XX. DOI. This article is © [Publisher’s Name] and
permission has been granted for this version to appear in e-Publications@Marquette. [Publisher] does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
[Publisher].]

11

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Data Analysis
All data are the means ± S.E. for n independent observations, and
statistical analyses were performed using Student's t test.
Concentration-response curves were analyzed using a four-parameter
logistic equation of the form, Y = Ymin + (Ymax − Ymin)/(1 +
10∧((logEC50 − X)*Hill slope)), where Y is the response at a given
concentration, Ymax and Ymin are the maximum and minimum response,
X is the logarithmic value of the concentration, and Hill slope is the
slope factor of the curve. EC50 (IC50 for inhibition) is the concentration
that gives a response halfway between Ymax and Ymin.

Results
Inhibition of NMDA-activated Currents by Bis(n)cognitins
To look into tether-dependent effects of the series of tacrine dimers
(i.e. bis(n)-cognitins) on NMDA receptors, we examined IC50 values of
bis(n)-cognitins to inhibit NMDA-activated currents and voltage
dependence of inhibition by using patch clamp techniques. In primary
cultured rat hippocampal neurons, 30 μm NMDA-activated currents
exhibited slight or no desensitization. As shown in Fig. 1A, bis(n)cognitins, when co-applied with NMDA, inhibited NMDA-activated
currents (INMDA) at a holding potential of −50 mV in a concentrationdependent manner. The IC50 value and slope factor for bis(propyl)cognitin were 0.52 ± 0.05 μm and 0.74 ± 0.04, respectively. By
comparison of the inhibitory effects of bis(n)-cognitins at holding
potentials from −70 to +50 mV, bis(propyl)-cognitin showed the
strongest voltage-dependent decrease of inhibition to INMDA (Fig. 1B).
The reversal potential value was not changed by bis(propyl)-cognitin.
Over the concentrations examined, none of bis(n)-cognitins applied
alone activated detectable currents.
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Bis(propyl)-cognitin Selectively Inhibits INMDA in an
Agonist-dependent Manner
We further examined the selectivity of bis(propyl)-cognitin
inhibition among ionotropic glutamate receptors. As shown in Fig. 2A,
bis(propyl)-cognitin had no detectable effect on steady-state currents
activated by 30 μm AMPA or kainic acid even at a concentration of 10
μm, although it inhibited INMDA by about 65% at 1 μm. We then tested
whether preapplication of bis(propyl)-cognitin had any effect on the
subsequent NMDA-activated currents. It was evident from Fig. 2B that
preapplied bis(propyl)-cognitin had no detectable effect on NMDAactivated currents, and bis(propyl)-cognitin could only exert an
inhibitory effect when NMDA receptors were activated by co- or
preapplication of NMDA, suggesting an agonist-dependent mechanism
of bis(propyl)-cognitin inhibition. Fig. 2C further demonstrated that
current amplitude of NMDA co-applied with bis(propyl)-cognitin
decreased gradually and reached a steady-state level within several
applications of NMDA in the presence of bis(propyl)-cognitin, and the
NMDA-activated current amplitude gradually recovered from the
blockade upon the repeated application of NMDA in the absence of
bis(propyl)-cognitin.

Bis(propyl)-cognitin Inhibits INMDA in an Uncompetitive
Manner
To distinguish possible patterns (competitive, noncompetitive,
or uncompetitive mechanism) of interaction between bis(propyl)cognitin and NMDA receptors, we examined the effect of a fixed
concentration of bis(propyl)-cognitin (0.3 μm) on currents activated by
NMDA at concentrations from 1 to 1000 μm. As shown in Fig. 3A, the
concentration-response curve for NMDA-activated currents was shifted
downward, with the maximum response reduced by about 50%. The
EC50 value (29.89 ± 3.37 μm versus a control value of 42.24 ± 3.84
μm; p < 0.05) and the slope factor of the NMDA concentrationresponse curve (0.99 ± 0.02 versus a control value of 1.11 ± 0.03; p
< 0.05) were decreased in the presence of bis(propyl)-cognitin. A
further plot of percentage inhibition against NMDA concentrations
revealed that the inhibitory effect increased with the increase of NMDA
concentration (Fig. 3A, inset). Furthermore, the concentration[Citation: Journal/Monograph Title, Vol. XX, No. X (yyyy): pg. XX-XX. DOI. This article is © [Publisher’s Name] and
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response curve for bis(propyl)-cognitin inhibition was shifted leftward,
with the IC50 value reduced from 0.52 μm (nH = 0.74) to 0.21 μm (nH
= 0.76) (p < 0.05).
Similarly, we investigated the effect of glycine on the
bis(propyl)-cognitin inhibition of INMDA by changing the glycine
concentrations from 0.1 to 10 μm in the external solution. As reported
by others, the decrease of glycine concentrations resulted in a
decrement of INMDA amplitude (data not shown). It could be seen from
Fig. 3B that the inhibitory effect of bis(propyl)-cognitin on INMDA
increased with the increase of glycine concentration in the external
solution. The concentration-response curve for bis(propyl)-cognitin
inhibition in the presence of 10 μm glycine was shifted leftward, with
the IC50 value decreased to 0.28 ± 0.02 μm from 1.23 ± 0.08 μm in
the presence of 0.1 μm glycine and with the slope factor basically
unchanged (0.79 for 10 μm glycine versus 0.74 for 0.1 μm glycine, p
> 0.05).

Bis(propyl)-cognitin Inhibition of INMDA Is of Fast Onset
and Offset Kinetics
The kinetics of onset and offset (τon and τoff) of the inhibition
were further investigated by fitting the changes of current amplitudes
upon the application and removal of bis(propyl)-cognitin with single
exponential functions. An example of single exponential fits to the
onset and offset of inhibition is shown in Fig. 4A. The inverse of the
onset and offset time constants derived from such fits was plotted as a
function of bis(propyl)-cognitin concentrations and fitted with linear
functions in Fig. 4B. The inverse of τon was significantly correlated with
bis(propyl)-cognitin concentrations (p < 0.001), indicating that
bis(propyl)-cognitin inhibition proceeded more quickly at higher
concentrations. The inverse of τoff was not correlated with bis(propyl)cognitin concentrations (p > 0.05). The mean value of τoff was 1911.5
± 207.2 ms. Based on the on- and off-rate time constants, a Kd value
of 0.68 μm was calculated for bis(propyl)-cognitin by the equation, Kd
= koff/kon (kon = (1/τon − 1/τoff)/[B3C]; koff = 1/τoff), which was close to
the value (0.52 μm) obtained from the concentration-response
relationship.

[Citation: Journal/Monograph Title, Vol. XX, No. X (yyyy): pg. XX-XX. DOI. This article is © [Publisher’s Name] and
permission has been granted for this version to appear in e-Publications@Marquette. [Publisher] does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
[Publisher].]

14

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Acting Site(s) Mapping for Bis(propyl)-cognitin on the
NMDA Receptor
To gain insight into the acting site(s) of bis(propyl)-cognitin on
the NMDA receptor, molecular docking simulation was performed.
Bis(propyl)-cognitin showed favorable interaction with the active site
of the ion channel of NMDA receptors, with a binding score of −29.76.
As a reference, a binding score of −33 was obtained for the known
NMDA receptor uncompetitive antagonist memantine. The NH group of
bis(propyl)-cognitin formed an additional hydrogen bond with the CO
group of Val640 of the NR2B (2.79 Å). The cyclohexane in the
bis(propyl)-cognitin molecule was located in the depth of the
hydrophobic pocket formed by Asn616 of the NR1 subunit and by Phe614
and Asn615 of the NR2B subunit (Fig. 5A). Furthermore, as illustrated in
Fig. 5B, bis(propyl)-cognitin apparently inhibited [3H]MK-801 binding
to NMDA receptors, with an IC50 value of 0.36 ± 0.07 μm (Ki = 0.27 ±
0.05 μm). It has been reported that the Asn616 residue in the pore
region is closely involved in the acting pocket of many open channel
blockers (29). We next examined the effect of NR1(N616R) mutation
on bis(propyl)-cognitin inhibition. As indicated in Fig. 5C, single
residue mutation in NR1 significantly reduced the inhibitory effect of
bis(propyl)-cognitin, with the IC50 value increased from 0.97 ± 0.13
μm to 45.51 ± 4.32 μm (n = 7, p < 0.001).

Bis(propyl)-cognitin Is Increasingly Effective in
Protecting against Escalating Levels of Glutamateinduced Excitotoxicity
We have previously reported that bis(heptyl)-cognitin prevents
glutamate-induced neuronal apoptosis in CGNs (24). In the current
study, the model of glutamate-induced excitotoxicity in CGNs was used
to investigate further the neuroprotective activities of bis(propyl)cognitin in vitro. Up to 30 μm, bis(propyl)-cognitin showed no
noticeable toxic effect on CGNs when applied alone (data not shown).
When CGNs were pretreated with bis(propyl)-cognitin at
concentrations from 0.1 to 30 μm for 2 h and exposed to 75 μm
glutamate for 24 h, it was found that bis(propyl)-cognitin prevented
glutamate-induced neuronal cell death in a concentration-dependent
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manner with an EC50 value of 1.33 ± 0.03 μm. The neuroprotection of
bis(propyl)-cognitin was more substantial than that of the same
concentration of memantine (Fig. 6A). Furthermore, it has been shown
in our previous study that the effectiveness of the neuroprotection of
bis(heptyl)-cognitin decreases with the increase of glutamate
concentrations, and it can hardly protect against 300–500 μm
glutamate-induced excitotoxicity (24). Very interestingly, however, the
neuroprotective activity of bis(propyl)-cognitin, in contrast to
bis(heptyl)-cognitin, increased with the escalation of glutamate
concentrations when CGNs were pretreated with 3 μm bis(propyl)cognitin and then exposed to glutamate (from 25 up to 500 μm) (Fig.
6B).

Bis(propyl)-cognitin Rescues MCAO-induced
Impairments Much More Potently than Memantine
The excitotoxicity associated with the NMDA receptor
overactivation is closely involved in the pathogenesis of stroke (15,
30). A transient focal ischemic stroke model of MCAO-induced
impairments in rats was employed to determine the neuroprotective
effect of bis(propyl)-cognitin in vivo. Adult male Sprague-Dawley rats
were subjected to transient MCAO for 2 h by the intraluminal suture
method, and intraperitoneal injection of saline or bis(propyl)-cognitin
(0.19 and 0.65 μmol/kg) was performed 15 min after MCAO onset. As
depicted in Fig. 7, the treatment with bis(propyl)-cognitin produced a
dose-dependent improvement in 24-h neurological deficits with
neurological scores reduced from 2.2 ± 0.60 (saline group) to 1.6 ±
0.24 and 0.5 ± 0.29 for 0.19 and 0.65 μmol/kg bis(propyl)-cognitintreated groups, respectively. Moreover, at 0.19 and 0.65 μmol/kg,
bis(propyl)-cognitin reduced the total infarct volume significantly from
a vehicle control of 34.92 ± 3.79% to 29.43 ± 5.33 and 11.24 ±
1.95% (n = 8–11 in each group, p < 0.01), respectively. Consistent
with the previous study (31), memantine at a dose of 93 μmol/kg
reduced the total infarct volume to 23.97%.

Bis(propyl)-cognitin Enhances LTP Induction
Based on the UFO characteristics of bis(propyl)-cognitin in
antagonizing NMDA receptors, we wanted to investigate the effect of
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bis(propyl)-cognitin on NMDA receptor-mediated physiological function
in terms of LTP. In rat hippocampal slices, HFS induced NMDA
receptor-dependent LTP under control conditions that reached a peak
immediately following HFS and then slowly declined over the next 1 h
to 45–80% above base line, and the averaged LTP was measured to
be 149 ± 3% at 60 min post-HFS (n = 6) (Fig. 8A). We next tested
the effect of bis(propyl)-cognitin on LTP induction. Bis(propyl)-cognitin
at a concentration of 1 μm did not change the base line but enhanced
LTP significantly compared with the LTP control (n = 5, p < 0.01) (Fig.
8), and the LTP was 172 ± 4% at 60 min post-HFS. Interestingly,
bis(propyl)-cognitin significantly increased LTP even at 10 μm,
although the effect was lower than that at 1 μm. To compare the effect
of different NMDA receptor antagonists, memantine and MK-801 were
also investigated. It was found that memantine at 3 μm did not alter
LTP induction. However, MK-801 at 1 μm was able to significantly
inhibit LTP induction (Fig. 8B).

Discussion
Excitotoxicity mediated by NMDA receptors has been thought to
be the final common pathway in a variety of neurological diseases.
NMDA receptor antagonists with the UFO properties and moderate
affinity are proposed to be effective and well tolerated in treating these
diseases (3, 11). In the current study, compared with memantine and
other dimeric AChE inhibitors derived from tacrine, the characteristics
of bis(propyl)-cognitin to inhibit NMDA receptors and its
neuroprotection in vitro and in vivo were investigated. We mainly
report three novel points; bis(propyl)-cognitin 1) is an uncompetitive
NMDA receptor antagonist with fast off-rate and moderate affinity, 2)
possesses superior neuroprotective activities against glutamateinduced excitotoxicity in vitro and MCAO-induced impairments in vivo,
indicating that this dimer may prevent glutamate-induced pathological
processes, and 3) enhances the LTP induction in hippocampal slices,
suggesting that this dimer may not interfere with but even promote
the NMDA receptor-mediated physiological functions.
Bis(propyl)-cognitin is an uncompetitive NMDA receptor
antagonist. We have reported that bis(heptyl)-cognitin, a dimeric AChE
inhibitor, is an antagonist of NMDA receptors (24). We speculate that
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other dimers from this series might also block NMDA receptors.
Indeed, bis(n)-cognitins can selectively inhibit NMDA-activated
currents with different extents of potency and voltage dependence. We
wonder whether some of these dimers are NMDA receptor antagonists
with the UFO properties. In comparing actions of the series of dimers
on NMDA receptors, we single out bis(propyl)-cognitin as a promising
UFO agent with moderate affinity based on moderate potency and
strong voltage dependence. Uncompetitivity is the major determinant
of safety and tolerability for NMDA receptor antagonists in clinical trials
(11, 16). To test whether bis(propyl)-cognitin inhibition is competitive,
non-competitive, or uncompetitive as defined by Lipton (11), we have
examined the effect of increasing NMDA concentrations on bis(propyl)cognitin inhibition. The concentration-response curve for NMDAactivated currents in the presence of bis(propyl)-cognitin is shifted
downward. This means that an increase of NMDA concentration cannot
overcome the inhibition of bis(propyl)-cognitin, suggesting that
bis(propyl)-cognitin inhibition is not via a competitive mechanism. A
further analysis of the agonist concentration dependence of
bis(propyl)-cognitin inhibition by plotting the percentage inhibition
against NMDA concentrations reveals that the inhibition increases with
the increase of NMDA concentration, which is characteristic of an
uncompetitive mechanism (10, 31). Different from memantine, which
has been demonstrated to act on the NMDA receptor with a quite slow
onset (32), bis(propyl)-cognitin inhibition exhibits fast onset and
reaches equilibrium during its application (several seconds). This can
exclude the possibility that the observed uncompetitive mechanism is
an artifact caused by an inadequate time of drug application.
Bis(propyl)-cognitin inhibits NMDA receptors in an agonistdependent manner. Because the inhibitory effect of uncompetitive
antagonists is contingent upon prior activation of the receptor channel
by the agonist (11), we have checked the agonist dependence of
bis(propyl)-cognitin. We observe that bis(propyl)-cognitin co-applied
or applied after the activation of NMDA receptors but not preapplied
shows an inhibitory effect on NMDA-activated currents. This
observation indicates that bis(propyl)-cognitin association with its
acting site on the receptor requires the channel to be open, which is
similar to the mechanism of action of memantine and MK-801, two
NMDA receptor uncompetitive antagonists (31, 33). These
observations strongly support the uncompetitive mechanism of action,
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which is further supported by the use dependence of action. Usedependent compounds can only access their site(s) of action when the
receptor/channel is in an activated state, resulting in a delay between
receptor activation and the antagonist-induced blockade. Therefore,
they are less likely to block short periods of activation, which typify
physiological activity of NMDA receptors (34).
Bis(propyl)-cognitin inhibition has the fast off-rate property.
Effective and safe NMDA receptor antagonists for the treatment of
neurodegenerative disorders are required to leave the channel quickly
when the membrane is depolarized under physiological conditions. To
meet this criterion, the antagonist is expected to inhibit the receptor
channel at negative membrane potentials and can leave the channel
quickly and have no effect at depolarized membrane potentials (e.g.
>−20 mV) (35). The observed strong voltage dependence of
bis(propyl)-cognitin inhibition of NMDA-activated currents may meet
this requirement, and more importantly, the inhibition exhibits a fast
off-rate (τoff ∼2 s), which is much faster than that of MK-801 (τoff ∼90
min) (33). This mechanism of action enables the quick elimination of
bis(propyl)-cognitin upon its removal or membrane depolarization,
suggesting that this compound should be safer than MK-801 (16). The
fast off-rate of bis(propyl)-cognitin also reflects its low affinity toward
NMDA receptors. Like memantine (16, 26), the onset time constants
are well correlated with bis(propyl)-cognitin concentrations, whereas
the offset time constants are independent of its concentrations. The
fast onset (millisecond to second time scale) of inhibition can also
exclude second messenger-mediated mechanism because the Gprotein-coupled cascade requires several tens of seconds for the
process of signal transduction (36), supporting the idea that
bis(propyl)-cognitin inhibits NMDA receptors directly.
Bis(propyl)-cognitin moderately blocks NMDA receptors at the
MK-801 site. To further characterize acting site(s) of bis(propyl)cognitin, we have applied molecular docking analysis to examine the
interaction between bis(propyl)-cognitin and NMDA receptors.
Bis(propyl)-cognitin exhibits favorable interaction with the channel
pore of the NMDA receptor at a similar binding score of memantine.
The interaction of bis(propyl)-cognitin with the channel pore region is
further proved by the fact that it moderately competes with [3H]MK801 binding to NMDA receptors. These results demonstrate that the
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acting site of bis(propyl)-cognitin may overlap with that of MK-801 in
the channel pore of the NMDA receptor. Previous study has shown that
mutation of NR1(N616R) significantly reduced the inhibitory potency of
Mg2+, memantine, and MK-801 (29). By using HEK293T cells
transfected with NR1(N616R)/NR2A, it is also demonstrated that the
inhibitory potency of bis(propyl)-cognitin is reduced. We speculate that
the mutation interferes with the binding of bis(propyl)-cognitin to the
region of MK-801 binding on NMDA receptors. The interaction between
bis(propyl)-cognitin and the NMDA receptors further supports the idea
that the inhibition is exerted by directly modulating NMDA receptors
rather than via a second messenger-mediated mechanism. Together,
these results suggest that bis(propyl)-cognitin is an NMDA receptor
antagonist at the MK-801 site with moderate affinity. Increasing
evidence has shown that the drugs with fast kinetics in moderately
inhibiting the targeted receptors and/or enzymes may have higher
therapeutic significance and hardly interfere with the physiological
function of the brain (35, 37, 38).
The UFO properties and moderate affinity are expected to
endow bis(propyl)-cognitin with increasing protective effectiveness
against escalating concentrations of glutamate-induced excitotoxicity
and enable its quick relief upon depolarization associated with
physiological neurotransmission without observable toxicity. Indeed,
we have found that, similar to memantine but in contrast to
bis(heptyl)-cognitin (24), bis(propyl)-cognitin is increasingly effective
in protecting against escalating levels of glutamate-induced
excitotoxicity without obvious cytotoxicity. Interestingly, a low
micromolar concentration of bis(propyl)-cognitin shows more
pronounced improvement in neurological scores and reduction in
infarct volume in rats subjected to MCAO than does memantine (31),
implying that bis(propyl)-cognitin may possess other relevant targets
in vivo. Our preliminary data show that this dimer does possess
selective inhibition on neuronal and inducible nitric-oxide synthase
instead of endothelial nitric-oxide synthase and inhibition of voltagegated calcium channels.4
We examined whether bis(propyl)-cognitin interferes with NMDA
receptor-mediated physiological functions by investigating its effect on
LTP induction in hippocampal slices. Similar to the previous report
(39), MK-801 significantly reduces LTP induction, whereas memantine
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at a relatively low concentration has no significant effect on LTP
induction, and the differential effects of MK-801 and memantine on
NMDA receptor-dependent LTP have been attributed to their different
affinities and voltage dependences to antagonize NMDA receptors.
Under the conditions of a resting membrane potential of around −70
mV, the ion channel of the NMDA receptor is blocked by Mg2+ ions.
Even if glutamate and glycine bind to the NMDA receptor, the Mg2+ ion
block prevents the flow of ions (35). The Mg2+ block can be removed
by depolarization of the cell membrane. In other words, the NMDA
receptor only allows Ca2+ ions entering the cell if two conditions are
fulfilled; the receptor must be activated by ligands, and the neuron
must be depolarized (e.g. by the activation of non-NMDA receptors).
An important aspect is that the Mg2+ block is reduced, even after slight
depolarization of the cell membrane to around −50 mV. With the
disruption of energy metabolism in neurodegenerative disorders,
glutamate is not cleared properly and may even be inappropriately
released; moreover, energetically compromised neurons become
depolarized (more positively charged) because in the absence of
energy the neurons cannot maintain their ionic homeostasis. This
depolarization (around −50 mV) relieves the normal Mg2+ block of
NMDA receptor-coupled channels because the relatively positive
charge in the cell repels positively charged Mg2+ from the channel
pore, and then excessive stimulation of NMDA receptors occurs.
Recent studies suggest that NMDA receptors are overstimulated in a
tonic rather than a phasic manner in several neurodegenerative
disorders. Memantine is an uncompetitive and moderate antagonist of
NMDA receptor with an appropriate voltage-dependent inhibition
between that of Mg2+ and MK-801. This property may help memantine
to inhibit the activation of NMDA receptors caused by a tonic and low
concentration (50–100 μm) glutamate under relatively low depolarized
conditions (about −50 mV; i.e. the aforementioned pathological
conditions), which is closely involved in neuronal damage and deficits
in synaptic plasticity, but not to interfere with the activation of NMDA
receptors caused by a phasic and high concentration (10 mm)
glutamate under high depolarized conditions (about −20 mV), which is
closely involved in physiological functions of glutamate and LTP
formation in synaptic plasticity (17, 35). As expected, bis(propyl)cognitin should not inhibit LTP induction because bis(propyl)-cognitin
has a profile similar to that of memantine for inhibition of NMDA
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receptors. However, to our surprise, bis(propyl)-cognitin is observed to
significantly enhance the LTP induction at 1 μm and without inhibition
even at 10 μm. This may be attributed to the increase of acetylcholine
levels caused by AChE inhibition by bis(propyl)-cognitin because
previous studies have reported that the hippocampus synaptic
transmission is enhanced by the activation of α7 nACh receptors linked
with a rise in intracellular calcium and transmitter release (40, 41). On
the other hand, bis(propyl)-cognitin has also been reported to inhibit
GABAA receptors (20), which may additionally contribute to the
facilitation of LTP (21,–23). LTP is widely considered to be one of the
major cellular mechanisms underlying learning and memory. The
enhancement of LTP by bis(propyl)-cognitin suggests that this dimer
might provide substantial therapeutic potentials for cognitive
impairments associated with neurodegenerative disorders.
Increasing evidence has shown that multifactorial
etiopathogenesis is clearly indicated in neurodegenerative disorders,
and multiple-drug therapy is required to address the varied
pathological aspects of these diseases (42). Current approaches with
one drug-one target only offer limited and transient benefits to
patients and do not significantly delay the course of neurodegeneration
(43). Multifunctional compounds might provide greater therapeutic
efficacy by targeting different sites in the brain concurrently (43, 44).
Therefore, new one drug-multiple target approaches have been
developed expressly to target multiple sites in the central nervous
system with single molecular entities for the treatment of these
diseases (42). Combining these novel findings with our previous
results (19, 20), we conjecture that over the same concentration
range (low to submicromolar range), bis(propyl)-cognitin concurrently
possesses anti-NMDA receptors, anti-GABAA receptors, and anti-AChE
activities. The synergism may provide bis(propyl)-cognitin as a
promising PAT drug candidate for effective prevention and treatment
and even modification of the pathological processes of
neurodegenerative disorders as well as the alleviation of the cognitive
impairments with fewer side effects.
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UFO uncompetitive NMDA receptor antagonist(s) with fast offrate
AChE acetylcholinesterase
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LTP long-term potentiation
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MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
EPSP excitatory postsynaptic potential
HFS high frequency stimulation.
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FIGURE 1.
Tether length differential potency and voltage dependence of bis(n)cognitins. A, the graph shows the inhibitory effects of memantine, tacrine,
and bis(n)-cognitins (B2C, B3C, B5C, B7C, and B10C) on 30 μm NMDAactivated currents at a holding potential of −50 mV in cultured rat
hippocampal neurons. Each point represents the mean of percentage
inhibition from 5–7 neurons. The IC50 values are indicated in the graph. Inset,
molecular structure of bis(propyl)-cognitin. B, voltage dependence of tacrine
and bis(n)-cognitin blockade of NMDA-activated currents is analyzed by
plotting the mean of percentage inhibition against holding potentials.
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FIGURE 2.
Selective, agonist- and use-dependent effects of bis(propyl)-cognitin
inhibition. A, current traces show the effect of 10 μm bis(propyl)-cognitin
(B3C) on 30 μm AMPA- or kainic acid (KA)-activated currents. Each row of
traces is recorded from the same neuron and repeated in five different
neurons. Bis(propyl)-cognitin is co-applied with AMPA or kainic acid for the
time course indicated above each trace. B, representative current traces
recorded from the same neuron show three different modes of drug
application: co-application of bis(propyl)-cognitin (0.3 μm) and NMDA (30
μm), co-application made after the onset of the response to NMDA, and
sequential application of NMDA following bis(propyl)-cognitin preapplication.
Note the different effects of bis(propyl)-cognitin under these different
conditions. A similar result was obtained in four different neurons. C,
representative current traces (top) and graph (bottom, n = 8) show the
control NMDA response and the cumulative inhibition incurred by consecutive
co-application of NMDA and 1 μm bis(propyl)-cognitin, followed by the
response to NMDA alone for recovery. Each response, normalized to the first
NMDA-activated current, is activated at intervals of 1 min. The solid bars
indicate the application of NMDA and/or bis(propyl)-cognitin.
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FIGURE 3.
Bis(propyl)-cognitin is an uncompetitive inhibitor of NMDA receptors.
A, NMDA dose-response curves in the absence (○) and presence (●) of 0.3 μm
bis(propyl)-cognitin (B3C). The steady state response for each concentration
of NMDA in the absence or presence of bis(propyl)-cognitin is normalized to
the response produced by 30 μm NMDA in the absence of bis(propyl)-cognitin
(marked with an asterisk). The responses are the means ± S.E. (error bars)
from 9–15 neurons at each concentration of NMDA. Inset, plot showing the
percentage inhibition of B3C and D(-)-2-amino-5-phosphonopentanoic acid
(AP5) against NMDA concentrations ranging from 3 to 300 μm. B, doseresponse relationships for bis(propyl)-cognitin inhibition of INMDA obtained
under the conditions of 0.1 μm (●) and 10 μm (■) glycine. The curves were
fitted using the logistic equation under “Experimental Procedures.”
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FIGURE 4.
Onset and offset time constants of bis(propyl)-cognitin inhibition. A,
traces show currents activated by 30 μm NMDA and its inhibition by 1 μm
bis(propyl)-cognitin applied after the activation of NMDA receptors. The
periods of drug application are indicated by the solid bar above the trace.
White dotted lines drawn through the current trace (black part) are the
theoretical fit of onset (τon) and offset (τoff) of bis(propyl)-cognitin inhibition
using single exponential functions. B, graph plotting average τon (■) and τoff
(●) values against bis(propyl)-cognitin concentration shows the concentration
dependence of onset and offset kinetics. Error bars, S.E.
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FIGURE 5.
Acting site of bis(propyl)-cognitin on the NMDA receptor. A, a close-up
view of the low energy pose of bis(propyl)-cognitin in the NMDA receptor
channel pore generated by molecular docking. The NMDA receptor is depicted
in ribbon form, bis(propyl)-cognitin (tan) is depicted as a stick model, and the
surface of the ligand pocket is shown as transparent gray skin. The homology
model of the ion channel of NMDA receptor is constructed based on the x-ray
crystal structure of the potassium channel KcsA (Protein Data Bank code
1BL8). B, graph shows the inhibition of [3H]MK-801 binding to rat in rat
cerebellar cortex membrane preparations by bis(propyl)-cognitin (B3C).
Membranes from rat cerebellar cortex were incubated with [3H]MK-801 (4
nm) and bis(propyl)-cognitin at gradually increasing concentrations. The data,
expressed as percentage of control, are means according to three
independent experiments. The Ki value was calculated from the corresponding
IC50 Value according to the equation, Ki = IC50/(1 + C/Kd), where C is the
concentration of radioligand and Kd is the dissociation constant obtained from
the saturation experiment (12 nm). C, representative current traces and plots
show the concentration-response relationships for bis(propyl)-cognitin
inhibition of currents mediated by recombinant NR1/NR2A (wild type (WT))
and NR1(N616R)/NR2A receptors expressed in HEK293T cells. Error bars, S.E.
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FIGURE 6.
Neuroprotection of bis(propyl)-cognitin in vitro. A, CGNs, at 8 days in
vitro, were preincubated with bis(propyl)-cognitin (B3C) at different
concentrations as indicated for 2 h and then exposed to 75 μm glutamate for
another 24 h. Cell viability is measured using an MTT assay. All of the data,
expressed as percentage of untreated control, are the means ± S.E. (error
bars) of three separate experiments. Inset, plots show dose-response
relationships for bis(propyl)-cognitin and memantine protection. B, CGNs, at 8
days in vitro, were preincubated with 3 μm bis(propyl)-cognitin (B3C) or
bis(heptyl)-cognitin (B7C) for 2 h and then exposed to different
concentrations of glutamate as indicated for another 24 h. The cell survival
after the treatment with glutamate or glutamate following bis(propyl)-cognitin
or bis(heptyl)-cognitin preincubation is expressed as percentage of untreated
control.

[Citation: Journal/Monograph Title, Vol. XX, No. X (yyyy): pg. XX-XX. DOI. This article is © [Publisher’s Name] and
permission has been granted for this version to appear in e-Publications@Marquette. [Publisher] does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
[Publisher].]

32

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

FIGURE 7.
Neuroprotective activity of bis(propyl)-cognitin in vivo. A,
representative 2,3,5-triphenyltetrazolium chloride-stained coronal brain
sections from animals of the sham group (left column), vehicle-treated control
group (middle column), and bis(propyl)-cognitin (B3C) (0.65 μmol/kg)treated group (right column), respectively. The white area represents the
area of infarction in the brains of stroke rats. Drug or saline was
intraperitoneally administered 15 min after the onset of MCAO, and rats were
decapitated 24 h later. B, infarct volume for seven sequential coronal sections
from anterior to posterior in rats receiving saline (Control) or bis(propyl)cognitin (0.65 μmol/kg) 15 min after the induction of ischemia. C, total infarct
volume (left) and neurological deficit scores (right) at 24 h after reperfusion
for saline-, bis(propyl)-cognitin (0.19 and 0.65 μmol/kg)-, and memantine
(93 μmol/kg)-treated rats, respectively. *, p < 0.05; **, p < 0.01 compared
with control. Error bars, S.E.

[Citation: Journal/Monograph Title, Vol. XX, No. X (yyyy): pg. XX-XX. DOI. This article is © [Publisher’s Name] and
permission has been granted for this version to appear in e-Publications@Marquette. [Publisher] does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
[Publisher].]

33

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

FIGURE 8.
Bis(propyl)-cognitin enhances LTP. A, the graph shows induction of LTP in
control (●) and in the presence of bis(propyl)-cognitin (B3C), perfused for 60
min prior to HFS (○). B, statistical analyses of the effect of bis(propyl)cognitin, memantine, and MK-801 on LTP. The agents were perfused over the
slices for 60 min prior to HFS, and LTP induction was recorded. All data are
the means ± S.E. of EPSPs at 60 min after HFS (n = 5). *, p < 0.05; **, p <
0.01 versus LTP control.
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